INTRODUCTION
Estrogens regulate the growth and differentiation of many normal and neoplastic tissues including breast, endometrial and ovarian tumors. 1, 2 Although the biological responses to estrogens are mainly mediated by estrogen receptors (ER)a and ERb, 3 ,4 the G protein-coupled receptor GPR30/GPER has been recently shown to also mediate estrogen signaling in a variety of normal and cancer cell types. 5 --8 In particular, GPER has been involved in rapid events induced by estrogens, including the transactivation of epidermal growth factor receptor, the activation of the mitogenactivated protein kinase and phosphoinositide3-kinase (PI3K) transduction pathways, the stimulation of adenylylcyclase and the mobilization of intracellular calcium (Ca 2 þ ). 7,9 --11 Accumulating evidence has also indicated that GPER signaling triggers a typical gene expression profile, as evidenced by diverse reports including microarray analysis. 11 --13 As far as the transcriptional regulation of GPER expression is concerned, our previous studies have demonstrated that EGFR ligands are able to transactivate the promoter of GPER and upregulate its mRNA and protein levels in cancer cells. 14, 15 Of note, the upregulation of GPER was associated with higher risk of developing metastatic disease in patients with breast cancer 16 and lower survival rates in endometrial cancer patients. 17 Insulin-like growth factor-I (IGF-I) belongs to a group of cellular and secreted factors (IGFs) that exert important roles in multiple biological systems. 18 --21 The IGF-I action is mediated by IGF-IR, a transmembrane heterotetramer, whose cytoplasmic tyrosine kinase domain is linked to diverse transduction cascades. 22, 23 Moreover, IGF-I is known to signal through AP-1 in breast cancer cells 24 and to stimulate the expression of genes involved in cell cycle progression, such as cyclin D1, by cross talking with estrogen-dependent pathways. 25 The interaction between IGF-I and ERa in regulating breast development and carcinogenesis has been well established. 26, 27 For instance, several studies have demonstrated that IGF-I induces the activation of ERa in a ligand-independent manner through the involvement of the mitogen-activated protein kinase signaling. 26, 28 Recently, increasing evidences have also extended our knowledge regarding the functional cross talk between growth factors transduction pathways and GPCR-activated signaling. 29 In this regard, we have previously shown that the EGFR system is involved in the GPER expression and function. 14, 15 In addition, a strict dependence of the IGF-I signaling on GPCRs was reported in many physiological functions 30 as well as in the development of diverse malignancies. 31 In the present study, we evaluated the ability of IGF-I to regulate GPER expression and function in ER-positive breast (MCF-7) and endometrial (Ishikawa) cancer cells. Our results demonstrate that the upregulation of GPER by IGF-I is mediated by the IGF-IR/PKCd/ ERK/c-fos/AP1 transduction pathway and involves ERa. As GPER was required for the IGF-I-induced cell migration and proliferation, our findings contribute to better understand the functional cross talk between these two important factors toward innovative therapeutic intervention in estrogen-sensitive tumors.
RESULTS

IGF-I induces GPER expression
In order to provide novel insights into the cross talk between IGF-I system and estrogen signaling, we sought to evaluate the ability of IGF-I to regulate GPER expression in breast MCF-7 and endometrial Ishikawa cancer cells. Interestingly, we found that IGF-I upregulates the mRNA and protein levels of GPER in both cell types (Figures 1a --d) . Next, we determined that the GPER protein induction is abrogated in the presence of the IGF-IR inhibitor AG1024 (AG), the MEK inhibitor PD98059 (PD), the PKC inhibitor GF109203X (GF) and the PKCd inhibitor Rottlerin (Rot), but it still persists using the PKA and phosphoinositide3-kinase inhibitors, H89 and LY294,002 (LY), respectively (Figures 1e --f) . Corroborating the aforementioned findings, the upregulation of GPER was also prevented by silencing IGF-IR expression (Figures 1g --j) .
In immunofluorescence studies performed in MCF-7 cells, IGF-I further confirmed the ability to upregulate GPER expression (Figure 2 ), an effect that was no longer observed transfecting cells with shGPER ( Figure 2 ). According to these observations, IGF-I Figure 1 . IGF-I upregulates GPER expression in MCF-7 and Ishikawa cells. (a, b) IGF-I induces GPER mRNA expression, as evaluated by realtime PCR. The mRNA expression of GPER was normalized to 18S expression. Results are shown as fold changes of mRNA expression upon treatment compared to cells treated with vehicle (À). (c, d) GPER protein levels were evaluated by immunoblotting in cells treated for 24 h with 100 ng/ml IGF-I. (e, f ) GPER protein expression was evaluated by immunoblotting in cells treated for 24 h with vehicle (À) or 100 ng/ml IGF-I alone and in combination with 10 mM IGF-IR inhibitor tyrphostin AG1024 (AG), 10 mM PKC inhibitor GF109203X (GF), 10 mM PKCd inhibitor Rottlerin (Rot), 10 mM MEK inhibitor PD98059 (PD), 10 mM PKA inhibitor H89, 10 mM PI3K inhibitor LY294,002 (LY), as indicated. (g --j) The upregulation of GPER protein levels by 100 ng/ml IGF-I was abrogated in the presence of shIGF-IR. Side panels show densitometric analysis of the blots normalized to b-actin. Each column represents the mean ± s.d. of three independent experiments performed in triplicate. J, K, ' Indicate Po0.05 for cells receiving vehicle (À) versus treatments. transactivated the GPER promoter construct transiently transfected in MCF-7 cells (Supplementary Figure 1) . Molecular mechanisms involved in the upregulation of GPER by IGF-I As the inhibitors of PKC and MEK transduction pathways prevented the upregulation of GPER induced by IGF-I, we then evaluated the activation of PKC and ERK in MCF-7 cells. IGF-I promoted rapid PKCd phosphorylation, which was no longer evident in the presence of the PKC inhibitors GF and Rot, while it was still present using the MEK inhibitor PD (Figure 3a) . Moreover, IGF-I also induced a rapid phosphorylation of ERK1/2, which was abolished by PD as well as by the PKC inhibitors GF and Rot (Figure 3b ). Taken together, these data suggest that ERK1/2 activation is downstream PKCd in MCF-7 cells treated with IGF-I.
It has been previously shown that the activation of the ERK transduction pathway leads to a rapid upregulation of c-fos, 11, 13, 32, 33 which has a relevant role in the growth stimulation of normal and cancer cells mainly forming the AP1 transcription complex with jun family members. 34 Accordingly, the ERK activation upon exposure to IGF-I was paralleled by the induction of c-fos (Figure 3c ). Of note, this response was abrogated using AG, GF, Rot and PD, suggesting that the IGF-IR/PKCd/ERK signaling mediates the regulation of c-fos induced by IGF-I in MCF-7 cells (Figure 3c ). Confirming the aforementioned data, IGF-I transactivated an AP1-luc-responsive collagenase promoter construct that was transiently transfected in MCF-7 cells, while the luciferase activity was abrogated in presence of AG, GF, Rot, PD (Figure 3d ) or co-transfecting a dominant-negative form of c-fos (DN/c-fos) (Figure 3e ). Of note, performing chromatin immunoprecipitation assay in MCF-7 cells, we ascertained that IGF-I induces the recruitment of c-fos to the AP1 site located within the promoter sequence of GPER (Figure 3f ). In accordance with these results, the transactivation of the GPER promoter construct by IGF-I was abolished co-transfecting the DN/c-fos (Figure 3g ) and the upregulation of the GPER protein levels was prevented in the presence of the DN/c-fos (Figure 3h ). Taken together, these findings indicate that the IGF-IR/PKCd/ERK/c-fos-AP1 transduction pathway mediates the transcription of GPER induced by IGF-I.
GPER is involved in the migration and proliferation promoted by IGF-I As CTGF is a major gene target of GPER activity, 12 we asked whether CTGF responds to IGF-I through GPER. In MCF-7 cells, IGF-I transactivated the CTGF promoter construct (Figure 4a ) and this effect was prevented silencing GPER expression. Likewise, the promotes the proliferation of cancer cells, 25, 26 we therefore asked whether a functional cross talk between IGF-I and GPER is involved in the growth responses to IGF-I. Notably, the proliferation induced by IGF-I in MCF-7 and Ishikawa cells was abolished by silencing GPER expression (Figures 6a and c) . In accordance with these observations, the upregulation of cyclin D1 induced by IGF-I in MCF-7 cells was abrogated knocking down GPER expression (Figure 6e ) or transfecting the DN/c-fos construct (Figure 6g ). In addition, a direct interaction between GPER and cyclin D1 was found upon exposure to IGF-I in MCF-7 cells (Figures 6h --i) . Collectively, these results suggest that GPER is involved in a signaling network that mediates the migration and proliferation induced by IGF-I in MCF-7 and Ishikawa cells.
ERa is involved in the regulation of GPER by IGF-I Considering the well known cross talk between IGF-I system and ERa in cancer cells, 27 we aimed at evaluating whether ERa is involved in the upregulation of GPER expression induced by IGF-I. Interestingly, the transactivation of the GPER promoter construct by IGF-I was prevented using the ERa inhibitor ICI 182,780 (ICI) (Figure 7a) . Accordingly, the increase of GPER protein levels by Using carcinoma-associated fibroblasts obtained from breast tumors, 35 we further confirmed the ability of IGF-I to upregulate the expression of GPER and its target gene CTGF 12 ( Supplementary  Figure 3) . Hence, the property of IGF-I to regulate GPER expression can be extended to these cancer surrounding cells, which mainly contribute to the malignant tumor features. 36 
DISCUSSION
Cross talk between estrogen and IGF-I signaling has been involved in several biological functions in breast cancer cells, including proliferation, survival, transformation, migration, adhesion and invasion. 37, 38 For instance, IGF-I transactivates ERa in a ligandindependent manner, 28 and activated IGF-IR interacts with ERa contributing to breast cancer development and progression. 39, 40 In addition, IGF-IR has been shown to be involved in non-genomic, membrane-associated ERa activity, 37 although many aspects remain to be further elucidated. In this regard, previous studies on the functional interaction between the IGF-I system and estrogens have focused only on estrogen signaling mediated by ERa. In recent years, the identification of GPER as a novel ER has opened a new scenario, which is still under investigation for the assessment of its full impact on the action of estrogens. Considering the functional cross talk between IGF-I and the estrogen-dependent pathways as well as the lack of data on the ability of IGF-I system to engage GPER in triggering biological responses, in the present study, we aimed to evaluate whether IGF-I could regulate GPER expression and function in MCF-7 and Ishikawa cancer cells. These cells express relatively low amounts of insulin receptors (IR) that may contribute to the formation of IR/IGF-IR hybrid receptors, which also bind to IGF-I with a slightly lower affinity than homotypic IGF-IR. 41 --43 Therefore, both MCF-7 and Ishikawa cells have low IR/IGF-IR content; 42, 43 hence, we believe that most of the IGF-I effects on GPER signaling are mediated by the homotypic IGF-IR.
Our results demonstrate that IGF-I transactivates the promoter of GPER and upregulates its expression at both mRNA and protein levels in MCF-7 and Ishikawa cancer cells. In particular, we show that the induction of GPER by IGF-I is mediated by sequential events such as the rapid activation of PKCd and ERK1/2 and the stimulation of c-fos, which is then recruited to an AP1 site located within the GPER promoter sequence. The functional role elicited by the AP1 complex is essential, as the transactivation of the GPER promoter sequence and the upregulation of GPER expression were abrogated by using a construct encoding for a dominant negative form of c-fos. Most importantly, GPER and its major target gene CTGF were required for cell migration induced by IGF-I. Given that CTGF primarily modulates and coordinates cell responses through the involvement of components of the extracellular matrix, 44, 45 the GPER/CTGF signaling activated by IGF-I might contribute to cell motility and invasion during cancer progression. Likewise, we also show that cell proliferation in response to IGF-I, requires a functional cross talk between GPER and the main cell cycle regulator cyclin D1. On the basis of the aforementioned observations, GPER may contribute to the intricate transduction network engaged by IGF-I in triggering important biological effects in cancer cells.
It has been largely reported that ERa mediates biological responses leading to the progression of estrogen-sensitive tumors. 46 In the classical model of action, ERa bound to the estrogen-responsive elements located within the promoters of target genes recruits an array of co-factors involved in the regulation of the transcriptional machinery. 24, 47 In addition, ERa modulates gene expression by a functional interaction with transcription factors, like AP1, 47 as well as with GPER as demonstrated in our previous studies. 11, 17 In this regard, the present data reveal that ERa is also involved in the IGF-Idependent regulation of GPER expression and therefore to GPER-mediated action. Hence, extending the current knowledge on the cross talk between ERa and GPER, our results indicate that these different ERs cooperate in mediating various extracellular stimuli leading to gene regulation and growth effects in cancer cells. Different forms of interaction between GPCRs and growth factor receptors have become increasingly evident in different cellular functions, 29 including cancer growth, angiogenesis and metastasis. 48 In particular, IGF-IR requires GPCRs in regulating many physiological functions. 49 Indeed, the cross talk between IGF-I and GPCR-dependent pathways occurs at multiple levels in a variety of malignancies. 50 For instance, a physical association between IGF-IR and the G protein subunits, Ga and Gbg, has been involved in cell migration in breast cancer cells. 51 In addition, IGF-I cooperated with agonists of GPCRs in promoting cell responses such as DNA synthesis, proliferation and anchorage-independent growth in pancreatic cancer cells. 31 The identification of GPER has expanded our understanding on the regulation and action of GPCRs. In this vein, it is worth to note that EGFR ligands transactivated the promoter of GPER and upregulated its expression in cancer cells. 14, 15 In addition, we have recently demonstrated that hypoxia, through the HIF-1a-mediated transduction pathway, induces GPER expression, hence suggesting a new mechanism by which estrogens may exert relevant biological effects under hypoxic conditions. 52 We have also found that GPER interacting with EGFR acts as a transcription factor in carcinomaassociated fibroblasts, 35 indicating the potential of GPER to affect cancer progression through the stimulation of cells surrounding tumors. Similarly, the present findings that GPER expression and function are regulated by IGF-I in cancer cells as well as in carcinoma-associated fibroblasts, shed new light on a novel mechanism by which the IGF-I system and estrogen signaling cooperate toward cancer development and progression. Of note, previous reports have shown that higher GPER levels were associated with worse clinical pathological features and lower survival rates in estrogen-sensitive tumors. 16, 17 Therefore, the expression levels of GPER may characterize not only the estrogen sensitivity and the response to endocrine pharmacological intervention in these tumors but could also be predictive of biologically aggressive phenotypes consistent with adverse outcome and survival. Thus, a better understanding on the GPER regulation and function represents a new challenge for a more comprehensive therapeutic approach in estrogen-responsive malignancies including breast and endometrial tumors. In this regard, our results further indicate that GPER is involved in an intricate tumorigenic transduction network, which should be considered as a promising therapeutic target toward innovative intervention.
MATERIALS AND METHODS Reagents
IGF-I, H89, LY294,002 (LY) and PD98059 (PD) were purchased from SigmaAldrich Corp. (Milan, Italy). Bisindolylmaleimide I (GF109203X) was bought from Santa Cruz Biotechnology (DBA, Milan, Italy), 3-bromo-5-t-butyl-4-hydroxybenzylidenemalonitrile (AG1024) and Rottlerin from Calbiochem (Milan, Italy). ICI 182,780 (ICI) was obtained from Tocris Chemicals (Bristol, UK). All compounds were solubilized in dimethylsulfoxide, except PD and IGF-I, which were dissolved in ethanol and in water, respectively.
Cell culture MCF-7 breast cancer cells were maintained in DMEM/F-12 (Invitrogen, Gibco, Milan, Italy) supplemented with 10% fetal bovine serum, 100 mg/ml penicillin/streptomycin and 2 mM L-glutamine (Sigma, Milan, Italy). Ishikawa endometrial cancer cells were maintained in DMEM (Invitrogen, Gibco) without phenol red supplemented with 10% fetal bovine serum 100 mg/ml penicillin/streptomycin and 2 mM L-glutamine (Sigma). Cells were switched to medium without serum the day before experiments; thereafter cells were treated as indicated. Primary fibroblast cells from breast cancer tissues were obtained as we have previously described 35 and cultured in RPMI-1640 medium supplemented with 20% fetal bovine serum, 100 mg/ml penicillin/streptomycin and 2 mM L-glutamine (Sigma).
Plasmids
The GPER luciferase expression vector promGPER was previously described. 52 The CTGF luciferase reporter plasmid promCTGF (-1999/ þ 36)-luc was a gift from Dr B Chaqour. 53 The luciferase reporter plasmid for AP-1-responsive collagen promoter was a kind gift from H van Dam (Department of Molecular Cell Biology, Leiden University, Leiden, Netherlands). As an internal transfection control, we cotransfected the plasmid pRL-TK (Promega, Milan, Italy) that expresses RenillaLuciferase. The plasmid DN/cfos, which encodes a c-fos mutant that heterodimerizes with c-fos dimerization partners but does not allow DNA biding, 54 was a kind gift from Dr C Vinson (NIH, Bethesda, MD, USA). The Sure Silencing (sh) IGF-IR, (sh) ERa and the respective control plasmids (shRNA), generated in pGeneClip Puromycin Vector, were purchased from SA Bioscience Corp. (Frederick, MD, USA) and used according to the manufacturer's recommendations (more information is available at www.sabiosciences.com). Short hairpin constructs against human GPER (shGPER) and CTGF (shCTGF) were obtained and used as previously described. 12, 14 In brief, they were generated in lentiviral expression vector pLKO.1 purchased by Euroclone, Milan, Italy. The targeting strand generated from the GPER shRNA construct is 5 0 -CGCTCCCTGCAAGCAGTCTTT-3 0 . The targeting strand generated from the CTGF shRNA construct is 5 0 -TAGTACAGCGATTCAAAGATG-3 0 .
Transfections and luciferase assays MCF-7 cells (1 Â 10 5 ) were plated into 24-well dishes with 500 ml/well of regular growth medium the day before transfection. The medium was replaced with DMEM lacking serum and phenol red on the day of transfection, which was performed using FuGene6 reagent, as recommended by the manufacturer (Roche Diagnostics, Milan, Italy), with a mixture containing 0.5 mg of reporter plasmid and 2 ng of pRL-TK. After 6 h the medium was replaced again with DMEM lacking serum and phenol red, treatments were added and cells were incubated for an additional 24 h. Luciferase activity was then measured with the Dual Luciferase Kit (Promega Italia, Milan, Italy) according to the manufacturer's recommendations. Firefly luciferase activity was normalized to the internal transfection control provided by the Renilla luciferase activity. The normalized relative light unit values obtained from cells treated with vehicle were set IGF-I regulates GPER expression and function P De Marco et al as onefold induction upon which the activity induced by treatments was calculated.
Reverse transcription and real-time PCR Total RNA was extracted using Trizol commercial kit (Invitrogen) according to the manufacturer's protocol. RNA was quantified spectrophotometrically, and its quality was checked by electrophoresis through agarose gel stained with ethidium bromide. Total cDNA was synthesized from RNA by reverse transcription using the murine leukemia virus reverse transcriptase (Invitrogen) following the protocol provided by the manufacturer. The expression of selected genes was quantified by real-time PCR using Step One (TM) sequence detection system (Applied Biosystems Inc, Milano, Italy), following the manufacturer's instructions. Gene-specific primers were designed using Primer Express version 2.0 software (Applied Biosystems Inc.). Assays were performed in triplicate, and the mean values were used to calculate expression levels, using the relative standard curve method. For GPER and the ribosomal protein 18S, which was used as a control gene to obtain normalized values, the primers were: 5 0 -ACACACC TGGGTGGACACAA-3 0 (GPER forward); 5 0 -GGAGCCAGAAGCCACATCTG-3 0 (GPER reverse); 5 0 -GGCGTCCCCCAACTTCTTA-3 0 (18S forward); and 5 0 -GGG CATCACAGACCTGTTATT-3 0 (18S reverse). Assays were performed in triplicate and the results were normalized for 18S expression and then calculated as fold induction of RNA expression.
Western blotting
Cells were grown in a 10-cm dishes and exposed to ligands before lysis in 500 ml of lysis buffer containing: 50 mM HEPES pH 7.5, 150 mM NaCl, 1.5 mM MgCl 2 , 1 mM EGTA, 10% glycerol, 1% TritonX-100, 1% sodium dodecyl sulfate (SDS), a mixture of protease inhibitors (Aprotinin, PMSF and Na-orthovanadate). Protein concentrations were determined according to the Bradford method (Sigma-Aldrich). Equal amount of whole protein extracts were electrophoreted through a reducing SDS/10% (w/v) polyacrilamide gel and transferred to a nitrocellulose membrane 
Co-immunoprecipitation
For co-immunoprecipitation of GPER/cyclin D1 complex, cells were lysed using 500 ml of RIPA buffer (Sigma) with a mixture of protease inhibitors (Aprotinin, PMSF and Na-orthovanadate). A total of 125 mg proteins were incubated overnight with 2 mg of GPER (N-15) or cyclin D1 (M-20) antibody and 20 ml of protein A/G agarose immunopreciptation reagent (Santa Cruz Biotechnology, Inc.). After four washes in PBS, samples were resuspended in 20 ml of SDS-sample buffer (0.5 M Tris--HCl pH 6.8, 20% glycerol, 2% SDS, 5% b-mercaptoethanol, 4% bromophenol blue). Western Blot analysis was performed as described above.
Chromatin immunoprecipitation
Cells grown in 10 cm plates were shifted for 24 h to medium lacking serum and then treated with vehicle or 100 ng/ml IGF-I for 3 h. Chip assay was performed as we have previously described. 52 The immune cleared chromatin was immunoprecipitated with anti c-fos (H-125) and anti ERa (F-10) antibodies or non-specific IgG (Santa Cruz Biotechnology, DBA).
A 4-ml volume of each immunoprecipitated DNA sample was used as template to amplify, by RT --PCR, one fragment of 261 bp, containing an AP-1 site, located into the GPER promoter region. The primer pairs used to amplify this fragment were: 5 0 -CGTGCCCATACCTTCATTGCTTCC-3 0 (forward) and 5 0 -CCTGGCCGGGTGTCTGTG-3 0 (reverse). Real-time PCR data were normalized with respect to unprocessed lysates (input DNA). Inputs DNA quantification was performed by using 4 ml of the template DNA. The relative antibody-bound fractions were normalized to a calibrator that was chosen to be the basal, untreated sample. Final results were expressed as percent differences with respect to the relative inputs.
Immunostaining assay
Fifty percent confluent cultured MCF-7 cells grown on coverslips were serum deprived and transfected for 12 h with a control shRNA or a shRNA specific for GPER (shGPR30), using Fugene 6 reagent, as recommended by the manufacturer, and then treated for 24 h with vehicle or 100 ng/ml IGF-I. Thereafter cells were fixed in 4% paraformaldehyde; permeabilized with 0.2% TritonX-100, washed three times with PBS, blocked and incubated overnight with a rabbit primary antibody GPR30 (N-15) (1:500; purchased from Santa Cruz Biotechnology). After incubation, the slides were extensively washed with PBS and incubated with donkey anti-rabbit IgG-FITC (1:500, from Santa Cruz Biotechnology) and propidium iodide (1:1000, Sigma-Aldrich). Leica AF6000 Advanced Fluorescence Imaging System supported by quantification and image processing software Leica Application Suite Advanced Fluorescence (Leica Microsystems CMS, GbH Mannheim, Germany) were used for experiments evaluation.
Proliferation assay
For quantitative proliferation assay, cells (1 Â 10 5 ) were seeded in 12-well plates in regular growth medium. Cells were washed once they had attached and then incubated in medium containing 2.5% charcoalstripped fetal bovine serum; when used, 500 ng of the indicated shRNA were added to cells using Fugene 6 reagent as recommended by the manufacturer and then renewed every 2 days before counting; treatments were added every day. Evaluation of cell growth was performed after 4 days using automatic counter (Countess -Invitrogen). Data shown are representative of three independent experiments performed in triplicate.
Migration assay
Migration assays were performed using Boyden chambers (Costar Transwell, 8 mm polycarbonate membrane). For knockdown experiments, cells were transfected with shRNA constructs directed against GPER or CTGF or ERa with an unrelated shRNA construct (3 mg DNA/well transfected with FuGene6 reagent in medium without serum). After 24 h, cells were seeded in the upper chambers. IGF-I was added to the medium without serum in the bottom wells. After 24 h, cells on the bottom side of the membrane were fixed and counted.
